BIOCRYST PHARMACEUTICALS INC — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
BioCryst adopted an amended non-employee director compensation policy effective June 1, 2026. Annual board retainer is $50,000; board chair receives additional $40,000. Committee chairs earn $10,000–$25,000 additional retainers; members earn $5,000–$12,500. New directors receive up to $500,000 in initial equity (60% options, 40% RSUs, pro-rated by months to next annual meeting); continuing directors receive $325,000 annually (60/40 split), both vesting over specified periods. Directors may elect to receive 50% or 100% of base retainer in stock instead of cash.
Why this rating
Routine director compensation policy amendment. Total annual board compensation (cash + typical equity grants) is immaterial relative to ~$1.9B market cap; standard governance practice with no material business or financial impact.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.